{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:26:26Z","timestamp":1780586786615,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272654"],"award-info":[{"award-number":["82272654"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903456"],"award-info":[{"award-number":["81903456"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejmech.2025.117283","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T21:41:48Z","timestamp":1737150108000},"page":"117283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Discovery of novel fluorine-containing parthenolide analogues as potential antitumor agents"],"prefix":"10.1016","volume":"286","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-0430","authenticated-orcid":false,"given":"Xiyan","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117283_bib1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1039\/C9NP00049F","article-title":"Advances in chemistry and bioactivity of parthenolide","volume":"37","author":"Freund","year":"2020","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2025.117283_bib2","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.drudis.2013.05.005","article-title":"parthenolide: from plant shoots to cancer roots","volume":"18","author":"Ghantous","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.117283_bib3","first-page":"814","article-title":"Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents","volume":"20","author":"Liu","year":"2022","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117283_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00044-023-03181-0","article-title":"Bioactivities and the structural modification of parthenolide: a review","volume":"33","author":"Wu","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.117283_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/B:DRUG.0000026256.38560.be","article-title":"Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer","volume":"22","author":"Curry","year":"2004","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2025.117283_bib6","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3390\/molecules23061478","article-title":"Parthenolide inhibits STAT3 signaling by covalently targeting Janus kinases","volume":"23","author":"Liu","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117283_bib7","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/acschembio.5b00945","article-title":"Strategies and approaches of targeting STAT3 for cancer treatment","volume":"11","author":"Furtek","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117283_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5483\/BMBRep.2019.52.7.152","article-title":"Highlighted STAT3 as a potential drug target for cancer therapy","volume":"52","author":"Lee","year":"2019","journal-title":"BMB Rep"},{"key":"10.1016\/j.ejmech.2025.117283_bib9","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1021\/acs.jmedchem.1c00629","article-title":"Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2147\/DDDT.S355059","article-title":"The emerging potential of parthenolide nanoformulations in tumor therapy","volume":"16","author":"An","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2025.117283_bib11","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1126\/science.1131943","article-title":"Fluorine in pharmaceuticals: looking beyond intuition","volume":"317","author":"Muller","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117283_bib12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1039\/B610213C","article-title":"Fluorine in medicinal chemistry","volume":"37","author":"Purser","year":"2008","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.117283_bib13","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1021\/jm800219f","article-title":"The many roles for fluorine in medicinal chemistry","volume":"51","author":"Hagmann","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115586","article-title":"Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023","volume":"258","author":"Han","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib15","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1021\/acs.jmedchem.9b01877","article-title":"Metabolic and pharmaceutical aspects of fluorinated compounds","volume":"63","author":"Johnson","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib16","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.31635\/ccschem.022.202201935","article-title":"A fruitful decade of organofluorine chemistry: new reagents and reactions","volume":"4","author":"Qing","year":"2022","journal-title":"CCS Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib17","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib18","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1021\/acs.jmedchem.5b00915","article-title":"Syntheses and biological evaluation of costunolide, parthenolide, and their fluorinated analogues","volume":"58","author":"Yang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib19","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1021\/jm5009456","article-title":"Total syntheses of parthenolide and its analogues with macrocyclic stereocontrol","volume":"57","author":"Long","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib20","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/acscentsci.9b00916","article-title":"Late-stage diversification of natural products","volume":"6","author":"Hong","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2025.117283_bib21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41570-021-00300-6","article-title":"Late-stage C-H functionalization offers new opportunities in drug discovery","volume":"5","author":"Guillemard","year":"2021","journal-title":"Nat. Rev. Chem"},{"key":"10.1016\/j.ejmech.2025.117283_bib22","doi-asserted-by":"crossref","first-page":"16890","DOI":"10.1021\/jacs.1c08920","article-title":"Late-stage diversification: a motivating force in organic synthesis","volume":"143","author":"Kim","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117283_bib23","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1039\/C9MD00297A","article-title":"Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia","volume":"10","author":"Li","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2025.117283_bib24","doi-asserted-by":"crossref","first-page":"7934","DOI":"10.1021\/jm201114t","article-title":"Fluorinated amino-derivatives of the sesquiterpene lactone, parthenolide, as 19F NMR probes in deuterium-free environments","volume":"54","author":"Woods","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib25","doi-asserted-by":"crossref","first-page":"8757","DOI":"10.1021\/jm301064b","article-title":"Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells","volume":"55","author":"Zhang","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib26","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.7150\/thno.41498","article-title":"ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma","volume":"10","author":"Tong","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.117283_bib27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00109-019-01839-0","article-title":"ACT001 modulates the NF-kappaB\/MnSOD\/ROS axis by targeting IKKbeta to inhibit glioblastoma cell growth","volume":"98","author":"Li","year":"2020","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117283_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.7150\/thno.49250","article-title":"Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1\/PI3K\/AKT signaling","volume":"11","author":"Hou","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.117283_bib29","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1021\/acs.jmedchem.9b01328","article-title":"Identification of parthenolide dimers as activators of pyruvate kinase M2 in Xenografts of Glioblastoma multiforme in vivo","volume":"63","author":"Ding","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib30","doi-asserted-by":"crossref","first-page":"116024","DOI":"10.1016\/j.ejmech.2023.116024","article-title":"Synthesis of melampomagnolide B derivatives as potential anti-Triple Negative Breast Cancer agents","volume":"264","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/cjoc.201900364","article-title":"Dehydroxylative trifluoromethylthiolation, trifluoromethylation, and difluoromethylation of alcohols","volume":"38","author":"Zhang","year":"2019","journal-title":"Chin. J. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib32","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1021\/ol402780k","article-title":"Copper-catalyzed decarboxylative trifluoromethylation of allylic bromodifluoroacetates","volume":"15","author":"Ambler","year":"2013","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2025.117283_bib33","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1021\/acs.joc.6b00628","article-title":"Copper-catalyzed O-difluoromethylation of functionalized aliphatic alcohols: access to complex organic molecules with an OCF2H group","volume":"81","author":"Levchenko","year":"2016","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jfluchem.2013.02.026","article-title":"The use of methyl 2,2-difluoro-2-(fluorosulfonyl)acetate as the difluorocarbene source to generate an in situ source of difluoromethylene triphenylphosphonium ylide","volume":"150","author":"Thomoson","year":"2013","journal-title":"J. Fluor. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cca.2019.01.011","article-title":"Ki-67 protein as a tumour proliferation marker","volume":"491","author":"Menon","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2025.117283_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bbrc.2016.10.100","article-title":"BCL-2: long and winding path from discovery to therapeutic target","volume":"482","author":"Schenk","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.117283_bib37","first-page":"346","article-title":"HDAC inhibitors, trichostatin A and valproic acid, increase E-cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells","volume":"40","author":"Wang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2025.117283_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104973","article-title":"Design, synthesis and in vivo anticancer activity of novel parthenolide and micheliolide derivatives as NF-KB and STAT3 inhibitors","volume":"111","author":"Zeng","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117283_bib39","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1535-7163.MCT-05-0030","article-title":"The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer","volume":"4","author":"Sweeney","year":"2005","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117283_bib40","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bmc.2016.12.036","article-title":"Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia","volume":"25","author":"Albayati","year":"2017","journal-title":"Bioorg. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:20:56Z","timestamp":1740381656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"alternative-id":["S0223523425000480"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117283","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel fluorine-containing parthenolide analogues as potential antitumor agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117283"}}